SRR1375203
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.482
- INFLAMMATORY_RESPONSE+0.420
- INTERFERON_GAMMA_RESPONSE+0.389
- COAGULATION+0.377
- PANCREAS_BETA_CELLS+0.370
- KRAS_SIGNALING_DN+0.359
- TNFA_SIGNALING_VIA_NFKB+0.335
- INTERFERON_ALPHA_RESPONSE+0.334
- ALLOGRAFT_REJECTION+0.322
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.282
Top 10 suppressed
- MYC_TARGETS_V1-0.594
- DNA_REPAIR-0.529
- MYC_TARGETS_V2-0.492
- OXIDATIVE_PHOSPHORYLATION-0.451
- UNFOLDED_PROTEIN_RESPONSE-0.441
- PROTEIN_SECRETION-0.434
- E2F_TARGETS-0.430
- MITOTIC_SPINDLE-0.382
- G2M_CHECKPOINT-0.379
- MTORC1_SIGNALING-0.364
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1374115 | GTEX | — | 0.954 |
| 2 | SRR1330699 | GTEX | — | 0.950 |
| 3 | SRR1334033 | GTEX | — | 0.948 |
| 4 | SRR1331289 | GTEX | — | 0.947 |
| 5 | SRR607647 | GTEX | — | 0.946 |
| 6 | SRR1082759 | GTEX | — | 0.944 |
| 7 | SRR8943034 | — | — | 0.942 |
| 8 | SRR1366961 | GTEX | — | 0.941 |
| 9 | SRR598894 | GTEX | — | 0.941 |
| 10 | SRR1321552 | GTEX | — | 0.940 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.482 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.389 | Idelalisib | — uncovered |
| COAGULATION | 0.377 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.359 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.335 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.334 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.322 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.282 | Inavolisib | — uncovered |
| COMPLEMENT | 0.279 | Inavolisib | — uncovered |
| MYOGENESIS | 0.241 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.238 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.205 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.201 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.199 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.156 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.152 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.137 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.133 | Inavolisib | — uncovered |